Clinical Trial

B-PaLMZ for TB Meningitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.
Protocol Amendment History 5 changes
critical Recruitment opened 2026-07-31
notable Primary completion moved earlier: 2030-08-31 -> 2028-03-31 2026-07-31
critical Primary endpoint(s) modified 2026-07-29
notable Sponsor changed: University of Minnesota -> David Boulware 2026-07-29
minor Completion pushed: 2030-08-31 -> 2030-09-30 2026-07-29
Trial Details
NCT Number NCT07227779
Lead Sponsor David Boulware
Collaborators: Infectious Diseases Institute, Uganda, University of Minnesota, Brighton & Sussex Medical School, Mbarara University of Science and Technology, Radboud University Medical Center, Meningitis Foundation
Conditions Tuberculous Meningitis, HIV, Meningitis, TB - Tuberculosis
Enrollment 240 participants
Start Date 2026-07-28
Primary Completion 2028-03-31 (estimated)
Study Completion 2030-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-30